China now represents 60% of clinical development in CAR-T therapy development globally: what have we learned to date and where are future opportunities?
Dr. Chen has over 15 years of experience as an oncology clinician and over 21 years of experience in the industry. Prior to joining Bioheng, Dr. Chen served as the Head of Medical Affairs and the Vice President at Takeda China, where he was responsible for supporting the launch and product cycle management of innovative products such as Adcetris ®, Entyvio ®, Vocinti ®, Takhzyro ®, Firazyr ®, Edarbi ® and myPKfit®. Additionally, he held executive positions in Medical Affairs at Bristol-Myers Squibb (BMS), Pfizer, and Sunway biotech.
He was a major contributor to the first NMPA approval for a lysing virus and was responsible for the pre-marketing and launch of several oncology products such as Sunitinib, Crizotinib, and Nabumetinib in China.
Dr. Chen holds an MD degree from the Army Medical University and has postdoctoral experience from Fudan University. He is currently a member of the CSCO Expert Committee on Tumor Bio-marker, the CSCO Expert Committee on Tumor Immunotherapy (IO), an Honorary Member of CACA Professional Committee on Oncology Drug Research, and the CSCO Expert Committee on Translational Medicine.
Weili Zhao, M.D., PhD, is a Professor of Hematology and the First Deputy Director of the Shanghai Institute of Hematology, and the Vice President and Associate Chief Physician of the Department of Hematology, at the Shanghai Ruijin Hospital. She is the doctoral supervisor of both Shanghai Jiao Tong University and the University Paris VII. Dr. Zhao is a foreign member of American Society of Hematology, the Vice President of the Chinese Association of Hematology, Secretary General of the Chinese Society of Experimental Hematology, and a member of the editorial committee of Pathobiology, Biomarker Research, at the Chinese Journal of Hematology, Chinese Journal of Leukemia & Lymphoma, and the Clinical Hematology Journal.
She mainly focuses on the clinical and basic research of hematological malignancies, especially the molecular mechanism and targeted therapy of malignant lymphoma. She innovatively proposed the molecular pathways of apoptosis, angiogenesis and cell differentiation involved in lymphoma progression and the availability of targeted agents for treatment.
Dr. Zhao has been awarded the National Award for Science and Technology Progress and Outstanding Achievement Award of Scientific Research from the National Ministry of Education and the HUA XIA Award of Medicine and Technology from the National Ministry of Science and Technology for her research. She is now leading projects granted by the National High Technology Research and Development Program of China, the National Natural Science Foundation of China and several other events on a provincial level. She has been honored New Century Excellent Talents in University by the State Ministry of Education. She has been honored as a Rising Star by the Program for New Century Excellent Talents in University by the State Ministry of Education, and Shu Gang Scholar by the Shanghai Municipal Educational Committee. She has published over 70 articles including those on leading hematology journals like cancer cell, nature genetics, blood, molecular cancer, and more, with total impact factors over 500.
Dr. Gu has a degree in Clinical Medicine from Fudan University, also previously known as Shanghai Medical University. With 8 years of physician experience in the internal medicine department in tertiary care hospital, Dr. Gu continues to contribute to her field intensively.
Dr. Gu has substantial experience with over 20 years of working at companies such as BI, AZ, BMS in the clinical research department. Dr. Gu has also worked as the head of CO for MNC of various industries for 16 years. Prior to joining PPC, she was a Senior VP of a leading China biotech company and carries rich experience after managing clinical, medical & regulatory affairs. With her wealth of experience, she has a deep insight into R&D needs and pathways for China's local biotech.
In addition, Dr. Gu also holds abundant experience across all the therapeutic areas in the clinical trials industry i.e onco, non-onco, such as Lung cancer, Liver cancers etc., PD- CLTA4, EGFR-TKI etc.
Dr. Xue gained his master's degree in Hematology from Shanghai Jiao Tong University and a doctor's degree in Oncology from Fudan University and has 17 years of experience in hematological oncology. He worked at Fudan University Shanghai Cancer Center from 2009 to 2018, and since 2019, he has worked in Shanghai Ruijin Hospital. In 2013-2014, he studied at Roswell Park Cancer Institute as a visiting scholar under the supervision of world-renowned lymphoma expert Myron Czucuman. Dr. Xue has led two multicenter clinical trials and participated in more than 40 Chinese/international trials in the field of hematological oncology.
Dr. Xue is currently a member of the Youth Committee of the Hematological Oncology Professional Committee, the Chinese Anti-Cancer Association, the Youth Committee of the Chinese Society of Clinical Oncology (CSCO), the Vice-Chairman of the Youth Committee,the Hematology Branch of the Shanghai Medical Association, and a member of the clinical research committee of antitumor drugs of the Shanghai Anti-Cancer association. He has published over 15 scientific papers and gave oral presentations at the 54th annual ASH meeting.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.